Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 16Other hematologic neoplasm 8Plasma cell 6Myeloid 5Thoracic 3Genitourinary 3Gynecologic 2Dermatologic 2CNS 2Breast 2Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Glioblastoma 4Ependymoma 3Prostatic Neoplasms 2Ovarian Neoplasms 2Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Leukemia 2Central Nervous System Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Brain Neoplasms 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Osteosarcoma 1Neurofibromatosis 1 1Neoplasms 1Myeloproliferative Disorders 1Melanoma 1Medulloblastoma 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Leukemia, Myelomonocytic, Juvenile 1

Interventions

Filgrastim 11Temozolomide 9Melphalan 9Cyclophosphamide 9Radiotherapy 7Busulfan 7Magnetic Resonance Spectroscopy 6Rituximab 5Psychiatric Rehabilitation 5Methotrexate 5Etoposide 5Cytarabine 5Carboplatin 5sargramostim 4fludarabine 4etoposide phosphate 4Thiotepa 4Nivolumab 4Methylprednisolone 4Flow Cytometry 4Alemtuzumab 4Vincristine 3Topotecan 3Specimen Handling 3Peripheral Blood Stem Cell Transplantation 3Pemetrexed 3Granulocyte Colony-Stimulating Factor 3Early Intervention, Educational 3Drug Therapy 3Dexamethasone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma × Azacitidine × CNS × Clear all
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT02223052 2020-05-12

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Celgene

Phase 1 Completed
89 enrolled
BreastCNSDermatologicGenitourinaryGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellSarcomaThoracic

Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glioblastoma, Hodgkin Disease, Kidney Neoplasms, Leukemia, Lung Neoplasms, Lymphoma, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Osteosarcoma, Skin Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡